$MAX

MediaAlpha, Inc. (MAX): Results of Operations and Financial Condition

MediaAlpha, Inc. (MAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 maxq22026-earningsreleasex.htm EX-99.1 Document Exhibit 99.1 MEDIAALPHA ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS Second Quarter Revenue Growth of 26%; Record Revenue of $316.9 million Second Quarter Net Income of $41.8 million; Adjusted EBITDA (1) of $29.3 millio

Original reporting
Published Jul 29, 2026, 8:07 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$MAX
Bullish
high confidence
Mentioned
$MAX
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MAXBullishHigh
01

Why it matters

Traders can update valuation and positioning based on the new Q2 print, the Q3 revenue and adjusted EBITDA ranges, and the company’s stated full-year free cash flow and remaining buyback plan.

02

Market read

Fresh earnings and guidance ranges plus buyback activity create a direct catalyst for MAX’s near-term trading and expectations into the Q&A call.

03

What to watch

The guidance includes an approximately $1M YoY decline in Contribution from under-65 Health; traders may focus on whether that segment weakness persists and offsets gains elsewhere.

Relevance 7/10Novelty 9/10Timing: after-hours/filing today, ahead of the Q&A call at 2:00 p.m. Pacific (5:00 p.m. Eastern)

Background

This is an SEC 8-K (Item 2.02) with MediaAlpha’s Q2 2026 results and forward guidance for Q3 2026 and the full year, plus details on share repurchases.

Company-level read

Ticker impact

$MAXBullishHigh confidence
Context

MediaAlpha reported Q2 2026 revenue of $316.9M (+26% YoY), net income $41.8M, and guided Q3 revenue $330M-$355M with EBITDA $32M-$35M.

Expected impact

Likely positive bias for MAX as the guidance range implies continued growth and rising adjusted EBITDA, with buyback support.

Evidence & confidence

The article discloses multiple new, decision-relevant datapoints: Q2 financial results, Q3 guidance ranges (revenue, contribution, adjusted EBITDA), and full-year free cash flow and remaining repurchase expectations.

Market effects

Signals strength in digital advertising spend migration within insurance lead-gen/marketplaces, potentially supportive for ad-tech and insurtech demand read-through.

No specific regional macro linkage beyond company operations; impact is primarily company-specific.

Limited direct global spillover; relevant mainly to US-listed ad-tech/insurance marketing platforms.

Counterpoint

Gross margin and contribution margin both declined YoY (gross margin 14.3% vs 15.0%, contribution 14.9% vs 15.8%), which could temper enthusiasm despite revenue growth.

Key entities

  • MediaAlpha, Inc.

    NYSE-listed digital advertising marketplace focused on insurance verticals; reported Q2 results and issued Q3/full-year guidance in the 8-K.

Related articles

$DRIMedAI 8/10

DRI Healthcare Reports Second Quarter 2026 Results and New Board Appointment

DRI Healthcare Trust (TSX: DHT.UN, DHT.U) reported Q2 2026 results for the quarter ended June 30, 2026: total income $50.1M, total cash receipts $46.5M, and adjusted EBITDA $42.6M. It repurchased 89,513 units at $11.65 and paid a $0.11/unit distribution. After quarter-end, it exercised a put option on Ekterly for about $178M and received FDA approval for Lumvoa (veligrotug), triggering $75M milestone payments.

$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.

$KDPMed

Keurig Dr Pepper Inc. Q2 2026 Earnings Call Summary

Keurig Dr Pepper reported Q2 2026 results that exceeded expectations, citing double-digit U.S. Refreshment Beverages growth and day-one integration of JDE Peet's. Dr Pepper Zero Sugar grew 30% in retail sales and energy reached 9% market share. U.S. Coffee faced margin pressure from hedging and tariffs. KDP reaffirmed low double-digit EPS growth for 2026 and low-double-digit legacy growth at the high end of 4% to 6%.